Chapter 4 - Immunohistochemistry in urothelial lesions
Published online by Cambridge University Press: 05 July 2016
- Type
- Chapter
- Information
- Pathology of the Urinary BladderAn Algorithmic Approach, pp. 187 - 196Publisher: Cambridge University PressPrint publication year: 2000
References
Further reading
Amin, MB, Trpkov, K, Lopez-Beltran, A, et al. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 2014;38:e20–34.CrossRefGoogle ScholarPubMed
Bassily, NH, Vallorosi, CJ, Akdas, G, et al. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma. Am J Clin Pathol 2000;113:383–8.CrossRefGoogle ScholarPubMed
Bing, Z, Zhang, PJ. Adult urinary bladder tumors with rhabdomyosarcomatous differentiation: clinical, pathological and immunohistochemical studies. Diagn Pathol 2011;6:66.CrossRefGoogle ScholarPubMed
Cessna, MH, Zhou, H, Perkins, SL, et al. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol 2001;25:1150–7.CrossRefGoogle ScholarPubMed
Chang, A, Amin, A, Gabrielson, E, et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am J Surg Pathol 2012;36:1472–6.CrossRefGoogle ScholarPubMed
Ching, CB, Amin, MB, Tubbs, RR, et al. HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. Mod Pathol 2011;24:1111–19.CrossRefGoogle ScholarPubMed
Council, L, Hameed, O. Differential expression of immunohistochemical markers in bladder smooth muscle and myofibroblasts, and the potential utility of desmin, smoothelin, and vimentin in staging of bladder carcinoma. Mod Pathol 2009;22:639–50.CrossRefGoogle ScholarPubMed
Edgecombe, A, Nguyen, BN, Djordjevic, B, et al. Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia. Appl Immunohistochem Mol Morphol 2012;20:264–71.CrossRefGoogle ScholarPubMed
Epstein, JI, Egevad, L, Humphrey, PA, Montironi, R. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 2014;38:e6–19.CrossRefGoogle ScholarPubMed
Gulmann, C, Paner, GP, Parakh, RS, et al. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract. Hum Pathol 2013;44:164–72.CrossRefGoogle ScholarPubMed
Gunia, S, Koch, S, Hakenberg, OW, et al. Different HER2 protein expression profiles aid in the histologic differential diagnosis between urothelial carcinoma in situ (CIS) and non-CIS conditions (dysplasia and reactive atypia) of the urinary bladder mucosa. Am J Clin Pathol 2011;136:881–8.CrossRefGoogle ScholarPubMed
Higgins, JPT, Kaygusuz, G, Wang, L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol 2007;31:673–80.CrossRefGoogle ScholarPubMed
Hodges, KB, Lopez-Beltran, A, Emerson, RE, et al. Clinical utility of immunohistochemistry in the diagnoses of urinary bladder neoplasia. Appl Immunohistochem Mol Morphol 2010;18:401–10.CrossRefGoogle ScholarPubMed
Jo, VY, Fletcher, CD. p63 immunohistochemical staining is limited in soft tissue tumors. Am J Clin Pathol 2011;136:762–6.CrossRefGoogle ScholarPubMed
Kaufmann, O, Volmerig, J, Dietel, M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol 2000;113:683–7.CrossRefGoogle ScholarPubMed
Kunju, LP, Mehra, R, Snyder, M, et al. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma. Am J Clin Pathol 2006;125:675–81.CrossRefGoogle ScholarPubMed
Lopez-Beltran, A, Luque, RJ, Mazzucchelli, R, et al. Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer. J Clin Pathol 2002;55:641–7.CrossRefGoogle ScholarPubMed
Lopez-Beltran, A, Santoni, M, Massari, F, et al. Bladder cancer: molecular determinants of personalized therapy. Curr Drug Targets 2015;16:115–24.CrossRefGoogle ScholarPubMed
Lotan, TL, Ye, H, Melamed, J, et al. Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma. Am J Surg Pathol 2009;33:1037–41.CrossRefGoogle ScholarPubMed
McKenney, JK, Amin, MB. The role of immunohistochemistry in the diagnosis of urinary bladder neoplasms. Semin Diagn Pathol 2005;22:69–87.CrossRefGoogle ScholarPubMed
McKenney, JK, Desai, S, Cohen, C, et al. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol 2001;25:1074–8.CrossRefGoogle ScholarPubMed
Miettinen, M, McCue, PA, Sarlomo-Rikala, M, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol 2014;38(1):13–22.CrossRefGoogle ScholarPubMed
Nascimento, AF, Fletcher, CD. Spindle cell rhabdomyosarcoma in adults. Am J Surg Pathol 2005;29:1106–13.CrossRefGoogle ScholarPubMed
Netto, GJ. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol 2012;9:41–51.CrossRefGoogle Scholar
Nicolas, MM, Tamboli, P, Gomez, JA, et al. Pleomorphic and dedifferentiated leiomyosarcoma: clinicopathologic and immunohistochemical study of 41 cases. Hum Pathol 2010;41:663–71.CrossRefGoogle ScholarPubMed
Ordonez, NG. Thrombomodulin expression in transitional cell carcinoma. Am J Clin Pathol 1998;110:385–90.CrossRefGoogle ScholarPubMed
Paner, GP, Shen, SS, Lapetino, S, et al. Diagnostic utility of antibody to smoothelin in the distinction of muscularis propria from muscularis mucosae of the urinary bladder: a potential ancillary tool in the pathologic staging of invasive urothelial carcinoma. Am J Surg Pathol 2009;33:91–8.CrossRefGoogle ScholarPubMed
Parker, DC, Folpe, AL, Bell, J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol 2003;27:1–10.CrossRefGoogle ScholarPubMed
Smith, SC, Mohanty, SK, Kunju, LP, et al. Uroplakin II outperforms uroplakin III in diagnostically challenging settings. Histopathology 2014;65(1):132–8.CrossRefGoogle ScholarPubMed
So, JS, Epstein, JI. GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma. Mod Pathol 2013;26:1365–70.CrossRefGoogle ScholarPubMed
Tacha, D, Zhou, D, Cheng, L. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol 2011;19:293–9.CrossRefGoogle ScholarPubMed
Tamas, EF, Epstein, JI. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains. Am J Surg Pathol 2007;31(3):390–7.CrossRefGoogle ScholarPubMed
Westenend, PJ, Stoop, JA, Hendriks, JG. Human papillomaviruses 6/11, 16/18 and 31/33/51 are not associated with squamous cell carcinoma of the urinary bladder. BJU Int 2001;88:198–201.CrossRefGoogle Scholar
Zhao, L, Antic, T, Witten, D, et al. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas. Am J Surg Pathol 2013;37(12):1876–81.CrossRefGoogle ScholarPubMed